Current Report Filing (8-k)
January 05 2017 - 6:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 30, 2016
CymaBay Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36500
|
|
94-3103561
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
7999 Gateway Blvd., Suite 130
Newark, CA 94560
(Address
of principal executive offices)
(510) 293-8800
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 1.01
|
Entry into a Material Definitive Agreement.
|
On December 30, 2016, CymaBay
Therapeutics, Inc. (the Company) entered into a definitive Exclusive License Agreement (the License Agreement) with Kowa Pharmaceuticals America, Inc. (Kowa). Pursuant to the License Agreement, the Company granted
to Kowa an exclusive license to certain patent rights and technology related to arhalofenate. Kowa will have exclusive rights to, among other things, develop, use, manufacture, sell and otherwise exploit the licensed technology in the United States
(including all possessions and territories). Under the License Agreement, Kowa has agreed to pay the Company an up-front payment of $5 million, potential milestone payments of $10 million based on the initiation of specific development
activities, potential milestone payments of $190 million upon the achievement of specified development and sales milestones, and a specified percentage of net sales of products produced from the licensed technology.
The foregoing is only a summary description of the terms of the License Agreement, does not purport to be complete and is qualified in its
entirety by reference to the License Agreement, which will be filed as an exhibit to the Companys Annual Report on Form 10-K for the year ended December 31, 2016.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
CymaBay Therapeutics, Inc.
|
|
|
By:
|
|
/s/ Sujal Shah
|
Name:
|
|
Sujal Shah
|
Title:
|
|
Chief Financial Officer
|
Dated: January 4, 2017
Cymabay Therapeutics (NASDAQ:CBAY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cymabay Therapeutics (NASDAQ:CBAY)
Historical Stock Chart
From Sep 2023 to Sep 2024